Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

921. Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels

-treatment serum prostate-specific antigen (PSA) levels were used to stratify patients, in order to determine whether any conclusions could be reached regarding the optimal therapy of the disease. Searching MEDLINE was searched from 1986 to 1996 for studies published in the English language, using the following search terms: 'prostatic neoplasms'; 'prostatic neoplasms' plus 'surgery'; 'prostatic neoplasms' plus 'radiotherapy'; 'prostate-specific antigen'. Study selection Study designs of evaluations (...) and the included studies. Bibliographic details Vicini F A, Horwitz E M, Gonzalez J, Martinez A A. Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels. Journal of Urology 1997; 158(2): 319-325 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Humans; Male; Prostate-Specific Antigen /blood; Prostatic Neoplasms /blood /therapy AccessionNumber 11997000947 Date bibliographic record published 31/03/1999 Date abstract record published 31/03/1999

1997 DARE.

922. Cost benefit of emerging technology in localized carcinoma of the prostate

Indexing Status Subject indexing assigned by NLM MeSH Adenocarcinoma /blood /pathology /radiotherapy; Cost-Benefit Analysis; Direct Service Costs; Disease-Free Survival; Humans; Male; Prospective Studies; Prostate-Specific Antigen /blood; Prostatic Neoplasms /blood /pathology /radiotherapy; Radiotherapy, Computer-Assisted /economics /methods; Technology, Radiologic /economics AccessionNumber 21997001488 Date bibliographic record published 30/11/1998 Date abstract record published 30/11/1998 NHS (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three dimensional conformal radiation therapy (3D CRT) in the treatment of localized prostate cancer. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients with clinical stage A2 (T1c) or B (T2) histologically confirmed carcinoma of the prostate. Setting Hospital. The economic study was carried out in Missouri, USA. Dates

1997 NHS Economic Evaluation Database.

923. Future benefits and cost-effectiveness of prostate carcinoma screening

primarily affected men aged over 70. The rate of distant disease decreased for both age groups. African-American men have distinctly more cores involved with carcinoma. Markov models demonstrated significant sensitivity to progression, complication and comorbidity rates. For treated carcinomas the QALY gains, compared with watchful waiting, ranged from -0.34 to 1.01 in well differentiated tumours, +0.33 to 5 years in moderately differentiated tumours, and between +1 and 8 years for poorly differentiated (...) differentiated tumours. Cost results The cost per carcinoma detected for men aged 55-70 years was $2,905. The cost per person screened for prostate specific antigen and digital rectal examination for African-American men was $849. Improving the specificity of screening tests has great cost reduction potential. Synthesis of costs and benefits Costs and benefits were not combined into cost-utility ratios. Authors' conclusions Current diagnostic trends toward the persistent increased detection of localised

1997 NHS Economic Evaluation Database.

924. Comparison of laparoscopic and minilaparotomy pelvic lymphadenectomy for prostate cancer staging in a community practice

, Cattolica E V. Comparison of laparoscopic and minilaparotomy pelvic lymphadenectomy for prostate cancer staging in a community practice. Urology 1997; 49(1): 60-63 PubMedID DOI Indexing Status Subject indexing assigned by NLM MeSH Aged; Cost-Benefit Analysis; Humans; Laparoscopy; Laparotomy; Lymph Node Excision /economics /methods; Lymphatic Metastasis; Male; Neoplasm Staging; Prostatic Neoplasms /pathology /surgery AccessionNumber 21997000200 Date bibliographic record published 28/02/1999 Date abstract (...) Comparison of laparoscopic and minilaparotomy pelvic lymphadenectomy for prostate cancer staging in a community practice Comparison of laparoscopic and minilaparotomy pelvic lymphadenectomy for prostate cancer staging in a community practice Comparison of laparoscopic and minilaparotomy pelvic lymphadenectomy for prostate cancer staging in a community practice St Lezin M, Cherrie R, Cattolica E V Record Status This is a critical abstract of an economic evaluation that meets the criteria

1997 NHS Economic Evaluation Database.

925. Cost-effectiveness analysis of prostatic cancer screening

. Bibliographic details Nakagawa S, Ebisui K, Sugimoto K, Nakanishi H, Kanemitsu N, Watanabe H. Cost-effectiveness analysis of prostatic cancer screening. Nippon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 1997; 88(10): 892-899 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Aged; Cost-Benefit Analysis; Humans; Japan; Male; Mass Screening /economics; Middle Aged; National Health Programs; Prostatic Neoplasms /economics /prevention & control AccessionNumber 21998006202 Date (...) Cost-effectiveness analysis of prostatic cancer screening Cost-effectiveness analysis of prostatic cancer screening Cost-effectiveness analysis of prostatic cancer screening Nakagawa S, Ebisui K, Sugimoto K, Nakanishi H, Kanemitsu N, Watanabe H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

1997 NHS Economic Evaluation Database.

926. Screening for prostate cancer (includes patient leaflet 'Information for men considering or asking for PSA tests')

. Unlike breast cancer screening, which has been shown to reduce mortality, prostate cancer screening has not yet been evaluated and there are several reasons why it may be less effective. Many men with prostate cancer never experience any ill effects because some tumours are slow growing and not aggressive. The most sensitive screening tests for prostate cancer are based on levels of prostate specific antigen (PSA). However, the PSA test and follow up biopsies cannot predict reliably whether a man has (...) for prostate cancer does more good than harm. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Mass Screening; Prostate-Specific Antigen; Prostatic Neoplasms Language Published English Country of organisation England Address for correspondence University of York, York YO10 5DD, United Kingdom. Tel: +44 1904 321040; Fax: +44 1904 321041; Email: crd@york.ac.uk AccessionNumber 31999008344 Date bibliographic record published 21/01/1999 Date abstract record published 21/01/1999 Health

1997 Health Technology Assessment (HTA) Database.

927. Brachytherapy for treatment of prostate cancer

Brachytherapy for treatment of prostate cancer Brachytherapy for treatment of prostate cancer Brachytherapy for treatment of prostate cancer Alberta Heritage Foundation for Medical Research Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Alberta Heritage Foundation for Medical Research. Brachytherapy for treatment of prostate cancer (...) . Alberta Heritage Foundation for Medical Research (AHFMR) 1997: 19 Authors' objectives This report has been prepared in response to a request for information on the status of brachytherapy as a treatment for prostate cancer. Currently in Alberta, external beam irradiation is used for patients with prostate cancer who require radiation treatment. There have been a number of recent requests for out-of-province referral of patients for brachytherapy treatment. Authors' conclusions The quality of evidence

1997 Health Technology Assessment (HTA) Database.

928. [Screening for prostatic carcinoma in dysuric patients: diagnostic protocols and cost-benefit analysis]

that EDR and the serum dosage of PSA are necessary and adequate methods in the programme of early diagnosis and screening of prostate neoplasms. Prostate echography should be reserved for cases of doubt and for the exclusion of needle biopsy. These measures also result in an optimisation of health expenditure. CRD COMMENTARY - Selection of comparators The reason for the choice of comparator is clear. The programme of early diagnosis of prostate cancer is based on a combination of different methods:EDR (...) [Screening for prostatic carcinoma in dysuric patients: diagnostic protocols and cost-benefit analysis] Screening del carcinoma prostatico in pazienti disurici: protocolli diagnostici e rapporto costi/benefici [Screening for prostatic carcinoma in dysuric patients: diagnostic protocols and cost-benefit analysis] Screening del carcinoma prostatico in pazienti disurici: protocolli diagnostici e rapporto costi/benefici [Screening for prostatic carcinoma in dysuric patients: diagnostic protocols

1997 NHS Economic Evaluation Database.

929. Diagnosis, management and screening of early localised prostate cancer

Diagnosis, management and screening of early localised prostate cancer Diagnosis, management and screening of early localised prostate cancer Diagnosis, management and screening of early localised prostate cancer Selley S, Donovan J, Faulkner A, Coast J, Gillat D Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Selley S, Donovan J (...) , Faulkner A, Coast J, Gillat D. Diagnosis, management and screening of early localised prostate cancer. Health Technology Assessment 1997; 1(2): 1-96 Authors' objectives To summarise the available evidence on the diagnosis, management and screening of early localised prostate cancer. Authors' conclusions There is no justification for the introduction of population screening. PSA testing should be limited to men with clinical evidence of prostate cancer who have a life expectancy of more than 10 years

1997 Health Technology Assessment (HTA) Database.

930. The diagnosis, management, treatment and costs of prostate cancer in England and Wales

The diagnosis, management, treatment and costs of prostate cancer in England and Wales The diagnosis, management, treatment and costs of prostate cancer in England and Wales The diagnosis, management, treatment and costs of prostate cancer in England and Wales Chamberlain J, Melia J, Moss S, Brown J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Chamberlain J, Melia J, Moss S, Brown J. The diagnosis, management, treatment and costs of prostate cancer in England and Wales. Health Technology Assessment 1997; 1(3): 1-53 Authors' objectives To inform NHS Commissioning Agencies about services of established or generally accepted value in the diagnosis and management of men with prostate cancer. To identify where possible their resource costs and comment on their cost-effectiveness. To identify areas where current ongoing research has

1997 Health Technology Assessment (HTA) Database.

931. The diagnosis, management, treatment and costs of prostate cancer in England and Wales Full Text available with Trip Pro

The diagnosis, management, treatment and costs of prostate cancer in England and Wales The diagnosis, management, treatment and costs of prostate cancer in England and Wales: a review Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find

1997 NIHR HTA programme

932. Diagnosis, management and screening of early localised prostate cancer Full Text available with Trip Pro

Diagnosis, management and screening of early localised prostate cancer Diagnosis, management and screening of early localised prostate cancer: a review Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need

1997 NIHR HTA programme

933. Cost-effectiveness of endorectal magnetic resonance imaging for the staging of prostate cancer

at least 1.2 years. Authors' conclusions The results show that endorectal magnetic resonance imaging techniques are more cost-effective than conventional magnetic resonance imaging for the staging of prostate cancer and that strict criteria should be used for the diagnosis of extracapsular disease. The authors indicated that, whilst they have shown the relative superiority of one magnetic resonance imaging method over another, they have not shown that either magnetic resonance imaging technique (...) Fellowship. Bibliographic details Langlotz C P, Schnall M D, Malkowicz S B, Schwartz J S. Cost-effectiveness of endorectal magnetic resonance imaging for the staging of prostate cancer. Academic Radiology 1996; 3(Supplement 1): S24-S27 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Cost-Benefit Analysis; Humans; Magnetic Resonance Imaging /economics; Male; Models, Economic; Neoplasm Staging /economics; Prostate /pathology; Prostatic Neoplasms /economics /mortality /pathology; Quality

1996 NHS Economic Evaluation Database.

934. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?

EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using first-line hormonal therapy combined with flutamide (CAB) versus first-line hormonal therapy alone (surgical orchiectomy or LhRH analogues) for prostate carcinoma patients with minimal or severe diseases. Type of intervention Treatment and secondary prevention. Economic study type Cost (...) -utility analysis. Study population 70 year old male patients with metastatic prostate carcinoma with severe or minimal disease. Setting Hospital. The economic study was carried out in the USA. Dates to which data relate Effectiveness and cost data were reported from three studies published in 1993 and 1995. No dates for the prices used were stated. Source of effectiveness data Effectiveness data were derived from a review of previously completed studies. Modelling A decision analysis model using

1996 NHS Economic Evaluation Database.

935. Goserelin or other gonadotrophin releasing hormone (GnRH) analogues in the treatment of advanced prostate cancer

in a high acceptance of orchidectomy (90%) in patients with hormone responsive disease. The authors therefore strongly recommend orchidectomy or goserelin for treatment of advanced prostatic cancer, but say that goserelin is considerably more expensive and has little to recommend it over orchidectomy. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Costs and Cost Analysis; Goserelin; Orchiectomy; Prostatic Neoplasms Language Published English Country of organisation England (...) of this assessment has been made for the HTA database. Citation Solomon C, Best L. Goserelin or other gonadotrophin releasing hormone (GnRH) analogues in the treatment of advanced prostate cancer. Southampton: Wessex Institute for Health Research and Development (WIHRD) 1996 Authors' objectives This report examines the costs and benefits of goserelin in first line palliative treatment of advanced prostate carcinoma, where it may be used as an alternative to orchidectomy. Authors' conclusions Orchidectomy is more

1996 Health Technology Assessment (HTA) Database.

936. Economic considerations of prostate cancer: the role of detection specificity and biopsy reduction

reduction. Cancer 1995; 75(7 Supplement S): 1987-1993 Indexing Status Subject indexing assigned by CRD MeSH Cost-Benefit Analysis; Decision Making; Humans; Male; Mass Screening /economics; Physical Examination /economics; Prostate-Specific Antigen /blood; Prostatic Neoplasms /economics /diagnosis; Sensitivity and Specificity AccessionNumber 21995000528 Date bibliographic record published 31/10/1998 Date abstract record published 31/10/1998 NHS Economic Evaluation Database (NHS EED) Produced (...) Economic considerations of prostate cancer: the role of detection specificity and biopsy reduction Economic considerations of prostate cancer: the role of detection specificity and biopsy reduction Economic considerations of prostate cancer: the role of detection specificity and biopsy reduction Littrup P J, Goodman A C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods

1995 NHS Economic Evaluation Database.

937. Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer

Other publications of related interest Hillner B E. Estimating the cost-effectiveness of flutamide in metastatic cancer. Cancer Treatment Reviews 1996;22(Supplement A):103-108. Indexing Status Subject indexing assigned by NLM MeSH Aged; Cost-Benefit Analysis; Flutamide /economics /therapeutic use; Humans; Male; Models, Theoretical; Neoplasm Metastasis; Prostatic Neoplasms /drug therapy /pathology AccessionNumber 21995000542 Date bibliographic record published 28/08/1997 Date abstract record (...) Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer Hillner B E, McLeod D G, Crawford E D, Bennett C L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief

1995 NHS Economic Evaluation Database.

938. Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men

17,000 prostate cancers at a cost of $76.1 million. Authors' conclusions The cost-effectiveness of strategies 1 and 2 is in the same range and may seem favourable. However, strategy 1 might seem less appropriate since it detects only two thirds of cancers treated for cure, while strategy 2 would probably occupy too many urological resources and would raise problems concerning availability. Strategy 4 detects only 50% of the tumours treated for cure, and has a lower cost-effectiveness than strategies (...) Gustafsson O, Carlsson P, Norming U, Nyman C R, Svensson H. Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men. Prostate 1995; 26(6): 299-309 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Aged; Cost-Benefit Analysis; Humans; Male; Mass Screening /economics /methods; Middle Aged; Physical Examination; Predictive Value of Tests; Prostate-Specific Antigen /blood; Prostatic Neoplasms

1995 NHS Economic Evaluation Database.

939. Prostate cancer screening in a large corporation population

Prostate cancer screening in a large corporation population Prostate cancer screening in a large corporation population Prostate cancer screening in a large corporation population Kantrowitz W, Doyle J, Semeraro J, Krane R J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability (...) of the study and the conclusions drawn. Health technology Prostate cancer screening. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Male employees of the Polaroid Corporation aged between 50 and 65 years. Setting Occupational. A large public corporation medical department in the United States. Dates to which data relate The start date of the screening programme was unclear. Resources used and costs were presented for the actual programme. The price year

1995 NHS Economic Evaluation Database.

940. Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review

Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review Hanley J A, McGregor M Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hanley J A, McGregor M. Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review. Montreal: Conseil d'Evaluation des Technologies de la Sante du Quebec (CETS). 1995 Authors' objectives To evaluate the benefits, adverse health effects and costs of screening asymptomatic men for cancer of the prostate. Authors' conclusions From

1995 Health Technology Assessment (HTA) Database.